The National Drug Abuse Treatment Clinical Trials Network

国家药物滥用治疗临床试验网络

• 批准号: 9461362
• 负责人: KATHLEEN M. CARROLL
• 金额: $ 40.06万
• 依托单位: MCLEAN HOSPITAL
• 依托单位国家: 美国
• 财政年份: 2002
• 资助国家: 美国
• 起止时间: 2002-09-30 至 2020-05-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/9461362
• 关键词: Accident and Emergency department; Address; Adolescent; Adult; Alcohol or Other Drugs use; Alcohols; Area; Boston; Buprenorphine; Caring; Child Care; Clinical; Clinical Research; Clinical Treatment; Clinical Trials Network; Cognitive Therapy; Communities; Computers; Connecticut; Data; Development; Diabetes Mellitus; Discipline of obstetrics; Doctor of Medicine; Doctor of Philosophy; Drug abuse; Drug usage; Effectiveness; Electronic Health Record; Emergency Care; Face; Fostering; Funding; Goals; HIV; Health care facility; Health system; Healthcare; Healthcare Systems; Hospital Departments; Hospitalization; Hospitals; Individual; Intervention; Intervention Studies; Leadership; Medical; Medical center; Medicine; National Institute of Drug Abuse; New England; Operative Surgical Procedures; Opioid; Patient Care; Patients; Pediatric Research; Peer Review; Play; Population; Pregnancy; Pregnant Women; Primary Health Care; Productivity; Psychiatric therapeutic procedure; Public Health; Publications; Recruitment Activity; Research; Research Infrastructure; Research Personnel; Research Project Grants; Risk; Seminal; Series; Site; Smoking; Substance Use Disorder; System; United States; Universities; Veterans; Work; addiction; base; chronic pain; cigarette smoking; clinical infrastructure; clinical practice; clinical research site; clinically relevant; cost efficient; effective therapy; efficacy research; efficacy trial; financial incentive; health care delivery; health information technology; high risk men; improved; improved outcome; innovation; innovative technologies; medical specialties; methamphetamine use; multidisciplinary; new technology; nicotine use in pregnancy; novel strategies; opioid misuse; patient registry; peer; pragmatic trial; public health relevance; rural area; screening and brief intervention; smoking cessation; standard of care; treatment program; trend; virtual

 DESCRIPTION: This is a competing renewal application for the New England Consortium Node (NECN), led by Kathleen Carroll, Ph.D., of Yale and Roger Weiss, M.D., of Harvard. The NECN has a track record of outstanding productivity in the Clinical Trials Network (CTN), with leadership of 4 highly successful trials, high levels of study participation, excellent recruitment and retention, and 64 peer-reviewed publications from CTN trial data during the current funding period. NECN investigators have first-authored all 3 of the most highly-cited CTN publications and all 4 CTN publications cited most often per year. The overarching goal of the NECN is to develop effective and sustainable interventions for substance use disorders that can be delivered in multiple healthcare settings, addressing substance use in all its diversity. Achieving this goal will entail 1) building on single-site efficacy trials to conduct multi-site effectivenes studies of promising interventions; 2) improving interventions with promising but modest results to date; and 3) developing innovative approaches for prevalent problems with no clearly established standard of care, or with suboptimal results in early studies (e.g., screening and brief intervention for drug use in primary care). To address these goals, the NECN has added 1) local, regional, and national hospital-based and primary care networks that cover millions of individuals, and 2) investigators from 7 New England universities who have conducted seminal work in addiction medicine and innovative technology (Drs. Fiellin, Higgins, Marsch, O'Connor, Saitz, Samet). The NECN research agenda demonstrates its capacity to develop and implement novel approaches to improve treatment for substance users wherever they contact the healthcare system. Proposed studies build on the previous work of NECN investigators and include, among others: 1. Screening and brief intervention (SBI) vs. repeated BIs vs. computer-based cognitive-behavioral therapy for risky drug use in primary care (Saitz, Carroll); 2. Financial incentives for pregnant smokers in obstetrical practice (Higgins); 3. Buprenorphine initiation in the emergency department vs. facilitated referral for opioid dependent patients (Fiellin, D'Onofrio); and 4. Use of peer navigators to enhance treatment retention among opioid dependent patients started on buprenorphine during hospitalization (Liebschutz, Stein).

 描述：这是新英格兰联盟节点（NECN）的竞争性续期申请，由Kathleen卡罗尔博士领导，耶鲁大学和罗杰韦斯，医学博士，是哈佛的毕业生NECN在临床试验网络（CTN）中具有出色的生产力记录，领导了4项非常成功的试验，高水平的研究参与，出色的招募 和保留率，以及在当前资助期内来自CTN试验数据的64篇同行评审出版物。NECN研究者首次撰写了所有3种最高引用的CTN出版物和每年最常引用的所有4种CTN出版物。 NECN的总体目标是为物质使用障碍制定有效和可持续的干预措施，这些干预措施可以在多种医疗环境中提供，解决各种物质使用问题。实现 这一目标将需要1）建立在单点功效试验的基础上，以进行有希望的干预措施的多点有效性研究; 2）改进迄今为止具有有希望但效果有限的干预措施;以及3）针对没有明确建立的护理标准的普遍问题，或在早期研究中具有次优结果的问题（例如，初级保健中药物使用的筛查和简短干预）。 为了实现这些目标，NECN增加了1）覆盖数百万人的地方、地区和国家医院和初级保健网络，以及2）来自7所新英格兰大学的研究人员，他们在成瘾医学和创新技术方面进行了开创性工作（Fiellin博士、希金斯博士、马施博士、奥康纳博士、塞茨博士、萨米特博士）。NECN的研究议程表明，它有能力开发和实施新的方法，以改善药物使用者的治疗，无论他们在哪里接触医疗保健系统。 拟议的研究建立在NECN调查人员以前的工作基础上，其中包括：1。筛查和简短干预（SBI）与重复BI与基于计算机的认知行为治疗在初级保健中的危险药物使用（Saitz，卡罗尔）; 2.对从事产科工作的怀孕吸烟者的财政奖励（希金斯）; 3.在急诊科开始丁丙诺啡与阿片类药物依赖患者的便利转诊（Fiellin，D 'Onofrio）;以及4.在住院期间开始使用丁丙诺啡的阿片类药物依赖患者中，使用同伴导航器提高治疗保留率（Liebschutz，Stein）。